Compare BNED & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNED | SIGA |
|---|---|---|
| Founded | 1965 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.6M | 309.8M |
| IPO Year | 2015 | 2016 |
| Metric | BNED | SIGA |
|---|---|---|
| Price | $12.14 | $3.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 370.5K | ★ 537.0K |
| Earning Date | 03-10-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $1,610,170,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $224.81 |
| P/E Ratio | $33.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.90 | $3.56 |
| 52 Week High | $14.75 | $9.62 |
| Indicator | BNED | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 37.18 |
| Support Level | $8.25 | N/A |
| Resistance Level | N/A | $4.84 |
| Average True Range (ATR) | 0.80 | 0.16 |
| MACD | 0.12 | -0.05 |
| Stochastic Oscillator | 37.65 | 37.28 |
Barnes & Noble Education Inc is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States. The company is also a textbook wholesaler and inventory management hardware and software provider. It offers course materials through physical and online bookstores, including new and used print textbooks, rental options, digital textbooks, and publisher-hosted digital courseware. Products are also offered directly to students through Textbooks.com. The majority of the company's revenue is derived from the sale of products through its bookstore locations, including virtual bookstores, and the bookstore affiliated e-commerce websites.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.